SRRK
Scholar Rock Holding Corporation
NASDAQ · Healthcare · Biotechnology · US
$55.33
−1.09%Aug 17, 2026, 23:04 UTC
Scholar Rock resubmitted a biologics license application for apitegromab, its SMA treatment, supported by an alternate fill-finish manufacturing facility, with an FDA decision date of September 30.
Source:Aug 7, 2026, 13:05 UTC
Scholar Rock resubmitted its biologics license application for apitegromab, with a FDA decision expected by September 30.
Aug 6, 2026, 00:00 UTC
Scholar Rock Holding Corp reported its Q2 2026 financial results, with zero revenue and a net loss of $109.9 million, or $0.84 per diluted share.
Source: